Ipsen expects total sales growth of more than 5% at constant exchange rates in 2025, supported by the continued expansion of products like IQIRVO, ONIVYDE, and Bylvay. However, Somatuline faces ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

FY 2024 total sales growth of 9.9% at CER1, or 8.7% as reported, with growth driven by strong performance across all therapeutic areas, including a 67.4% increase in the Rare ...

CIRBP Family, Tumors, Molecular Mechanisms, RNA-Binding Proteins, Cellular Stress Share and Cite: Cai, Y. , Wang, T. and Zhan ...

A new blood test could help doctors detect pancreatic cancer earlier, potentially improving survival rates for one of the ...

Wells Fargo analyst Mohit Bansal upgraded Jazz Pharmaceuticals (JAZZ) to Overweight from Equal Weight with a price target of $170, up from ...